Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 109 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ February 10, 2019 Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... July 27, 2022 FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes July 14, 2020 Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... November 21, 2020 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell... A Genome-Wide Association Study of irAEs Identifies New Genome-Wide Significant Associations...
